- Chronic migraine affects up to 20 million people worldwide
- Medication overuse emerges as a significant risk factor for chronic migraine progression
- Atogepant, a calcitonin gene-related peptide receptor antagonist, demonstrated effectiveness in reducing mean monthly migraine days
- Mindfulness therapy alongside usual care showed potential in reducing headache frequency
- Emphasis on comprehensive treatment approaches involving both pharmacologic and non-pharmacologic interventions
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
